Answers are grounded in this paper and cite their sources.
Reveals dual-target properties of meroterpenoids in promoting Aβ clearance and reducing generation in a zebrafish model.
Seven undescribed filicinic acid-based meroterpenoids, hyperjaponiones A-G (1-7), along with a new natural product (hyperjaponione H, 8) and 10 known analogues (9-18), were isolated from Hypericum japonicum Thunb. Chiral separation of compound 1 afforded a pair of racemates (±)-1 (1a and 1b). Their structures were elucidated through a comprehensive spectroscopic analysis and quantum chemical calculations. Moreover, biological evaluation revealed that 8 activated peroxisome proliferator-activated receptor-γ (PPARγ) transcription and upregulated the level of ATP-binding cassette transporter A1 (ABCA1), showing promise in promoting β-amyloid (Aβ) clearance. Surface plasmon resonance analysis indicated that 8 might interacted with the PPARγ ligand-binding domain, with an estimated binding affinity (Kd) of 5.63 μM. Molecular docking study further predicted the binding mode of 8 to PPARγ. Additionally, 8 was found to inhibit β-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, showing potential in reducing Aβ generation. In an in vivo zebrafish model, 8 exhibited notable anti-Alzheimer's disease effects with no detectable toxicity or teratogenicity. Thus, 8 acts as a dual-target agent by both activating PPARγ and inhibiting BACE1, highlighting its potential as a novel therapeutic candidate for Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: